240 related articles for article (PubMed ID: 32565177)
1. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma.
Lu KH; Lu EW; Lin CW; Yang JS; Yang SF
Pharmacol Ther; 2020 Oct; 214():107611. PubMed ID: 32565177
[TBL] [Abstract][Full Text] [Related]
2. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.
Iguchi T; Miyakawa Y; Saito K; Nakabayashi C; Nakanishi M; Saya H; Ikeda Y; Kizaki M
Int J Oncol; 2007 Aug; 31(2):285-91. PubMed ID: 17611684
[TBL] [Abstract][Full Text] [Related]
3. Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.
Li S; Chen P; Pei Y; Zheng K; Wang W; Qiu E; Zhang X
Med Sci Monit; 2019 Feb; 25():1429-1438. PubMed ID: 30796194
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
Cheng HL; Lin CW; Yang JS; Hsieh MJ; Yang SF; Lu KH
Oncotarget; 2016 Mar; 7(9):9742-58. PubMed ID: 26848867
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study.
Smith AA; Lindley SES; Almond GT; Bergman NS; Matz BM; Smith AN
Vet Med Sci; 2023 Jan; 9(1):59-67. PubMed ID: 36398717
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Byrum ML; Pondenis HC; Fredrickson RL; Wycislo KL; Fan TM
J Vet Intern Med; 2016 Jul; 30(4):1187-96. PubMed ID: 27251585
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma.
Meier D; Lodberg A; Gvozdenovic A; Pellegrini G; Neklyudova O; Born W; Fuchs B; Eijken M; M Botter S
Cancer Med; 2021 Jan; 10(1):286-296. PubMed ID: 33179858
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
Ouyang Z; Li H; Zhai Z; Xu J; Dass CR; Qin A; Dai K
Curr Drug Targets; 2018; 19(5):409-421. PubMed ID: 26073860
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Young RJ; Coleman RE
Future Oncol; 2013 May; 9(5):633-43. PubMed ID: 23647292
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid in the management of metastatic bone disease.
Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3β activation.
Li S; Li JJ
Neoplasma; 2019 Sep; 66(5):766-775. PubMed ID: 31288526
[TBL] [Abstract][Full Text] [Related]
15. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
16. HER-2 involvement in osteosarcoma.
Gill J; Geller D; Gorlick R
Adv Exp Med Biol; 2014; 804():161-77. PubMed ID: 24924174
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.
Westbrook JA; Wood SL; Cairns DA; McMahon K; Gahlaut R; Thygesen H; Shires M; Roberts S; Marshall H; Oliva MR; Dunning MJ; Hanby AM; Selby PJ; Speirs V; Mavria G; Coleman RE; Brown JE
J Pathol; 2019 Mar; 247(3):381-391. PubMed ID: 30426503
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in osteosarcoma.
Brown HK; Tellez-Gabriel M; Heymann D
Cancer Lett; 2017 Feb; 386():189-195. PubMed ID: 27894960
[TBL] [Abstract][Full Text] [Related]
19. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
20. Role of ezrin in osteosarcoma metastasis.
Ren L; Khanna C
Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
